1800-272-662
Shopping Cart 0
countryflagAU
Login

Quoin Pharmaceuticals Ltd DRC

Healthcare US QNRX

8.58USD
-0.0073(0.09%)

Last update at 2026-03-11T14:57:00Z

Day Range

8.418.88
LowHigh

52 Week Range

0.6012.00
LowHigh

Fundamentals

  • Previous Close 8.59
  • Market Cap2.87M
  • Volume44107
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-9.27480M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-6.48

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -9.38150M -21.46259M -2.09536M -1.56040M 15.32M
Minority interest - - - - -
Net income -9.27745M -8.51867M -1.76405M -1.56040M 15.32M
Selling general administrative 6.58M 4.50M 1.43M 1.51M 7.97M
Selling and marketing expenses - - - - -
Gross profit - - - - -0.28000M
Reconciled depreciation 0.10M 0.10M 0.10M 0.02M -
Ebit -8.84869M -20.37218M -2.04834M -1.56040M -
Ebitda -8.74465M -20.26814M -1.94430M -1.53969M 15.32M
Depreciation and amortization 0.10M 0.10M 0.10M 0.02M -
Non operating income net other - - - - -
Operating income -8.84869M -20.37218M -2.04834M -1.56040M 15.32M
Other operating expenses 9.26M 6.06M 1.67M 1.56M 16.22M
Interest expense 0.71M 1.09M 0.05M 0.00000M -
Tax provision - - - - -
Interest income 0.10M - - - -
Net interest income -0.61834M -1.36541M -0.04702M 0.00000M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.10404M -12.94392M -0.33131M - -
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M -0.28000M
Total operating expenses 9.26M 6.06M 1.67M 1.56M 16.22M
Cost of revenue - - - - -
Total other income expense net -0.53280M -1.09041M -0.04702M - -
Discontinued operations - - - - -
Net income from continuing ops -9.38150M -21.46259M -2.09536M -1.56040M -
Net income applicable to common shares -9.44676M -21.46259M -2.09536M -1.56040M -
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 12.17M 14.46M 9.36M 1.38M 21.32M
Intangible assets 0.58M 0.70M 0.81M 0.91M -
Earning assets - - - - -
Other current assets 0.59M 0.52M 1015.47M 0.14M -
Total liab 6.51M 7.05M 8.70M 7.99M 0.40M
Total stockholder equity 5.66M 7.41M 0.66M -6.60730M -
Deferred long term liab - - - - -
Other current liab 3.05M 2.92M 7.78M 6.77M 1.88M
Common stock - -2932.00000M 31.66M 0.00010M 0.00010M
Capital stock 0.00000M 0.00000M 0.00000M 0.00000M -
Retained earnings -46.20359M -37.51675M -28.06998M -6.60740M -100.86400M
Other liab - - 0.37M - -
Good will - - - - -
Other assets - 0.38M 0.05M - 0.89M
Cash 2.40M 2.86M 7.48M 0.32M 18.11M
Cash and equivalents - - - - -
Total current liabilities 3.58M 3.53M 8.70M 7.99M 0.40M
Current deferred revenue -0.00060M - -743.84000M - -
Net debt -2.39769M -2.86063M 736.36M 0.89M -17.71000M
Short term debt 0.00060M - 743.84M 1.21M 0.40M
Short long term debt - - - 1.21M -
Short long term debt total 0.00352M - 743.84M 1.21M 0.40M
Other stockholder equity 51.87M 2976.92M 28.73M 0.00010M 100.86M
Property plant equipment - - - - -
Total current assets 11.29M 13.37M 8.50M 0.47M 18.11M
Long term investments - - - - -
Net tangible assets - 6.70M -0.15157M -7.51994M -5.52862M
Short term investments 8.29M 9.99M - - -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.53M 0.61M 0.92M 0.00000M -
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00000M - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.30M 0.38M 0.05M -1.93700M -
Deferred long term asset charges - - - - -
Non current assets total 0.88M 1.09M 0.86M 0.91M 2.32M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -0.45568M -10.14912M -0.62500M -0.12500M -9.89912M
Change to liabilities - -0.21781M 1.35M 0.23M 0.24M
Total cashflows from investing activities - -10.14912M -0.62500M -0.12500M -0.12500M
Net borrowings - -0.91167M 3.31M 1.93M 1.30M
Total cash from financing activities 5.22M 14.01M 13.50M 1.79M 1.30M
Change to operating activities - 0.12M -0.01868M 0.05M 0.05M
Net income -8.66419M -9.38150M -21.46259M -2.09536M -1.56040M
Change in cash -0.45945M -4.62214M 7.16M -4.91821M 5.24M
Begin period cash flow 2.86M 7.48M 0.32M 5.24M 0.00004M
End period cash flow 2.40M 2.86M 7.48M 0.32M 5.24M
Total cash from operating activities -7.84416M -8.48073M -5.72009M -1.33863M -1.29886M
Issuance of capital stock - - - - -
Depreciation 0.10M 0.10M 0.10M 0.10M 0.02M
Other cashflows from investing activities - -0.25000M -0.62500M -0.12500M -0.12500M
Dividends paid - 65.27M - - -
Change to inventory - - - -0.06019M 0.36M
Change to account receivables - - - 0.06M 0.11M
Sale purchase of stock - -14.81912M - - -
Other cashflows from financing activities 5.22M 79.59M 6.87M 1.79M -4.83954M
Change to netincome - 0.89M 14.03M 0.38M 0.38M
Capital expenditures 0.00000M 0.25M 0.62M 0.12M 0.12M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.10M -0.09435M 1.33M 0.27M 0.24M
Stock based compensation 1.09M 0.76M 0.00000M - -
Other non cash items 53.45M 0.13M 14.31M 0.38M -0.51277M
Free cash flow -7.84416M -8.73073M -6.34509M -1.46363M -1.42186M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
QNRX
Quoin Pharmaceuticals Ltd DRC		 -0.0073 0.09% 8.58 - - - 0.48 -0.4219
NVO
Novo Nordisk A/S		 0.16 0.41% 38.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.005 0.01% 38.74 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -4.89 0.98% 494.28 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 3.71 0.48% 775.75 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

Quoin Pharmaceuticals Ltd DRC

42127 Pleasant Forest Court, Ashburn, VA, United States, 20148-7349

Key Executives

Name Title Year Born
Dr. Michael Myers Ph.D. Co-Founder, CEO & Chairman 1962
Ms. Denise Carter Co-Founder, COO & Director 1969
Mr. Gordon Bruce Dunn J.D. Chief Financial Officer 1964

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.